Tag: BCMA CAR-T for myeloma

Home / BCMA CAR-T for myeloma

Categories

Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma

SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and sol...
bcma-car-t-for-myeloma

After amazing growth of CAR T-Cell therapy: what’s next?

The future of CAR T-cell therapy: an analysis of its rapid growth and expansion. Within the realm of contemporary medicine, CAR T-cell therapy emerges as an innovative and groundbreaking intervention...
bcma-car-t-for-myeloma

Scan the code